MAPK1 and breast cancer: Lower miR-550a-3p or higher ERK1, ERK2, and pERK1/2 were significantly associated with poorer overall survival (OS) and disease-free survival (DFS) for breast cancer patients (Figure 1D), suggesting that miR-550-3p reduction is a prognostic risk factor for both poorer OS and DFS in breast cancer.